Walk down the sleep-aid aisle of almost any pharmacy or scroll through a wellness retailer's website, and cannabinol — better known by its abbreviation, CBN — is everywhere, marketed in gummies, tinctures, and capsules as a "non-psychoactive" cousin of THC that gently eases people into sleep. A new study from the University of Connecticut, published in the journal Drug and Alcohol Dependence, suggests that gentle reputation deserves a second look: in mice, repeated CBN exposure produced both tolerance and withdrawal symptoms strikingly similar to those seen with THC.
Mice Stopped Responding to CBN Within Days
Led by researcher Olivia Vanegas and senior author Steven Kinsey, the study gave mice CBN twice daily for three consecutive days. By the end of that short window, the animals had become measurably less responsive to the compound's effects — the hallmark of pharmacological tolerance. That a tolerance effect emerged after just three days of twice-daily dosing is notable given how CBN products are typically used: nightly, often for weeks or months at a stretch, by people chasing consistent sleep benefits.
Withdrawal Symptoms Mirrored THC Dependence
The more striking finding came when the researchers stopped the CBN or administered a drug that blocks cannabinoid receptors, forcing withdrawal. The mice displayed head twitching and paw fluttering — behaviors researchers consider physical markers of cannabinoid withdrawal, comparable to shaking and tremor seen in human drug withdrawal. In a separate arm of the study, mice that had been trained to recognize the subjective effects of THC generalized that same recognition to CBN, treating the two compounds as pharmacologically interchangeable — despite CBN's reputation as a milder, non-intoxicating alternative. The researchers also reported that CBN suppressed immune responses at doses too low to produce any psychoactive-like effect, adding another dimension to its biological footprint beyond sleep.
A Compound That Has Outrun the Evidence Behind It
CBN occurs naturally in only trace amounts in the cannabis plant; most of the CBN sold commercially is synthesized by degrading THC, then marketed on the strength of consumer buzz rather than clinical trial data. Unlike melatonin or prescription sleep medications, CBN products sold as supplements face no FDA requirement to prove they're safe or effective for sleep before reaching store shelves, and dosing varies widely between brands. The UConn findings are the first to systematically document tolerance and withdrawal from CBN specifically, rather than inferring its effects from better-studied cannabinoids like THC or CBD.
Kinsey and his colleagues were careful to frame the results as a starting point rather than a verdict: the study was conducted in mice, using repeated short-interval dosing that may or may not mirror how people actually use commercial CBN gummies, and it does not prove that the people currently taking these products nightly are developing dependence. But it does establish, for the first time in a controlled setting, that the biological machinery for tolerance and withdrawal is there.
What This Means for Patients
Anyone using CBN gummies or tinctures as a nightly sleep aid should treat them the way they would any substance capable of producing tolerance — as something to use intermittently rather than indefinitely, and to taper rather than stop abruptly if symptoms like irritability or disrupted sleep appear after quitting. Because CBN supplements are unregulated, potency and purity can vary significantly between brands, making it hard to know exactly how much a given gummy is delivering. Patients who find themselves needing more of a CBN product over time to get the same sleep benefit — one of the clearest behavioral signs of tolerance — should talk to a physician about evidence-based alternatives, such as cognitive behavioral therapy for insomnia or FDA-approved sleep medications, rather than simply increasing their dose.
